Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from BICO Group AB Class B ( (SE:BICO) ) is now available.
BICO Group AB has completed the divestment of its subsidiaries MatTek and Visikol to Sartorius for USD 80 million, with net proceeds of USD 77.2 million after transaction costs and adjustments. This divestment aligns with BICO’s updated strategy to focus on lab automation and selected workflows, and the proceeds will be used to strengthen the company’s balance sheet. The financial impact of the transaction will be reflected in the Q2 2025 interim report, and MatTek and Visikol will be treated as discontinued operations from Q2 2025.
More about BICO Group AB Class B
BICO is a lab automation partner and provider of selected workflows to the pharmaceutical and biotech industries. With over 48,000 instruments installed in more than 65 countries, BICO’s products, software, and solutions are utilized in over 3,500 laboratories, including the world’s top 20 pharmaceutical companies. The company operates through two business areas: Lab Automation and Life Science Solutions, and is listed on the Mid-Cap, Nasdaq Stockholm under BICO.
Average Trading Volume: 173,282
Current Market Cap: SEK2.55B
For an in-depth examination of BICO stock, go to TipRanks’ Overview page.